Short Stocks Picks Based on Artificial Intelligence: Returns up to 42.89% in 3 Months

Short Stocks Picks

This forecast is part of the Top 10 Stocks Package, as one of I Know First’s systematic trading tools. The full package includes a daily prediction for a total of 20 stocks with bullish and bearish signals:

  • Top 10 stocks pick for the long position
  • Top 10 stocks pick for the short position


Package Name: Top 10 Stocks
Recommended Positions: Short
Forecast Length: 3 Months (09/24/2018 – 12/24/2018)
I Know First Average: 25.38%
Short Stocks Picks

10 out of 10 top stock picks from the algorithm decreased as predicted for this long-term forecasting period. NBIX saw monumental growth of 42.89% in just 3 Months. ALNY, and HRTX also had excellent performances with returns of 33.73% and 29.84% respectively. The package had an overall average return of 25.38%, providing investors with a premium of 45.13% over the S&P 500’s return of -19.75% during the same period.

Neurocrine Biosciences, Inc., incorporated on March 20, 1996, is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. The Company’s late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist in Phase III development for endometriosis and uterine fibroids that is partnered with AbbVie Inc.; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase (COMT) inhibitor. Its product pipeline also includes NBI-640756 and NBI-74788. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems, which include therapeutic categories ranging from hypothalamic-pituitary-adrenal (HPA) disorders to stress-related disorders and neurological/neuropsychiatric disease. Its subsidiaries include Neurocrine Continental, Inc., Neurocrine Europe, Ltd. and Neurocrine Therapeutics, Ltd.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Algorithmic Stock Forecast: The table on the left is a stock forecast produced by I Know First’s algorithm. Each day, subscribers receive forecasts for six different time horizons. Note that the top 10 stocks in the 1-month forecast may be different than those in the 1-year forecast. In the included table, only the relevant stocks have been included. The boxes are arranged according to their respective signal and predictability values (see below for detailed definitions). A green box represents a positive forecast, suggesting a long position, while a red represents a negative forecast, suggesting a short position.

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.